Andere talen Tenaya Therapeutics, Inc.

Aandelen

TNYA

US87990A1060

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 10-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
4,2 ^USD	-6,25%		-9,09%	+29,63%

21/03	TENAYA THERAPEUTICS, INC. : Canaccord Genuity herhaalt koopadvies	ZM
18/03	Tenaya Therapeutics, Inc. rapporteert winstresultaten voor het volledige jaar dat eindigde op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Tenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual Meeting	02/05
North American Morning Briefing : Stock Futures -2-	19/03
Tenaya Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	18/03
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	18/03
Tenaya Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	18/03
Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine	18/03
Tenaya Therapeutics, Inc. Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine	18/03
Tenaya Therapeutics to Participate in Upcoming March Investor Conferences	27/02
Tenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature Communications	26/02
Tenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature Communications	26/02
Tenaya Therapeutics Insider Bought Shares Worth $9,999,999, According to a Recent SEC Filing	14/02
Tenaya Therapeutics Announces Pricing of Underwritten Offering	08/02
Tenaya Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference	03/01
Tenaya Therapeutics to Participate at the 35th Annual Piper Sandler Healthcare Conference	21/11
Tenaya Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08/11
Tenaya Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update	08/11
Tenaya Therapeutics Gets FDA Clearance For TN-401 Gene Therapy Trial	26-10-23
Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy	26-10-23
Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy	26-10-23
Tenaya Therapeutics Presents Encouraging New Clinical and Preclinical Data from HDAC6 Inhibitor Program TN-301 for the Potential Treatment of Heart Failure with Preserved Ejection Fraction at the 2023 HFSA Annual Scientific Meeting	09-10-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Tenaya Therapeutics, Inc.

Aandelen

TNYA

US87990A1060

Andere talen

Filters